ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 007,62
1,47%
Dow Jones
44 747,63
-0,28%
DAX
21 902,42
1,63%
Brent Oil
74,515
0,47%
Bitcoin
97 546,69
1,01%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. KemPharm Inc (KMPH)

  7. KemPharm Inc (KMPH) Actualités

KMPH

KemPharm (KMPH)

KemPharm Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KMPH
DateHeureSourceTitreSymboleSociété
25/06/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
25/06/202423h11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KMPHKemPharm Inc
29/04/202413h49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KMPHKemPharm Inc
10/04/202422h23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KMPHKemPharm Inc
10/04/202413h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KMPHKemPharm Inc
09/04/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KMPHKemPharm Inc
03/04/202422h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KMPHKemPharm Inc
01/04/202423h27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KMPHKemPharm Inc
26/06/202322h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KMPHKemPharm Inc
15/05/202323h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KMPHKemPharm Inc
15/05/202322h23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KMPHKemPharm Inc
17/04/202322h26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KMPHKemPharm Inc
16/03/202311h02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prrn14a)NASDAQ:KMPHKemPharm Inc
15/03/202312h04Edgar (US Regulatory)Proxy Statment - Contested Solicitations (definitive) (defc14a)NASDAQ:KMPHKemPharm Inc
13/03/202321h30Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:KMPHKemPharm Inc
07/03/202323h31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KMPHKemPharm Inc
07/03/202323h28Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KMPHKemPharm Inc
01/03/202313h43GlobeNewswire Inc.Zevra Therapeutics Begins Trading as ZVRANASDAQ:KMPHKemPharm Inc
28/02/202314h00GlobeNewswire Inc.Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)NASDAQ:KMPHKemPharm Inc
27/02/202322h30GlobeNewswire Inc.Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary ProxyNASDAQ:KMPHKemPharm Inc
27/02/202322h11Edgar (US Regulatory)Proxy Statement - Contested Solicitations (preliminary) (prec14a)NASDAQ:KMPHKemPharm Inc
27/02/202313h30GlobeNewswire Inc.Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 ResultsNASDAQ:KMPHKemPharm Inc
24/02/202313h30GlobeNewswire Inc.Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
23/02/202313h30GlobeNewswire Inc.Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023NASDAQ:KMPHKemPharm Inc
22/02/202314h50GlobeNewswire Inc.CORRECTION – KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
22/02/202313h30GlobeNewswire Inc.KemPharm Announces Corporate Name Change to Zevra TherapeuticsNASDAQ:KMPHKemPharm Inc
31/01/202313h30GlobeNewswire Inc.KemPharm Enhances Senior Management TeamNASDAQ:KMPHKemPharm Inc
24/01/202313h30GlobeNewswire Inc.KemPharm Issues Letter to ShareholdersNASDAQ:KMPHKemPharm Inc
18/01/202313h30GlobeNewswire Inc.KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and AdvocacyNASDAQ:KMPHKemPharm Inc
11/01/202313h30GlobeNewswire Inc.KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development OfficerNASDAQ:KMPHKemPharm Inc
 Showing the most relevant articles for your search:NASDAQ:KMPH

Dernières Valeurs Consultées

TSX
TPU
TD US Equity Index ETF
BOV
RECV3T
Petroreconcavo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces